Menu Search

Company Announcements

Latest announcements

Date and timeCompanyHeadlineSource
Air Transat (TSX: TRZ) - A deplorable situation demonstrating the Board of Directors' inability to ensure the company's long-term viability.Canada Newswire
Data Published in the New England Journal of Medicine Confirm the Long-term Durability and Safety of HEMGENIX® (etranacogene dezaparvovec-drlb) Over Five YearsPR Newswire
Dyne Therapeutics to Host Investor Conference Call and Webcast to Review Topline Results from Registrational Expansion Cohort (REC) of DELIVER Clinical Trial of Z-Rostudirsen (DYNE-251) in Duchenne Muscular Dystrophy; Tomorrow, December 8 at 8:00 a.m. ETGlobeNewswire
Rigel Presents Updated Data from the Ongoing Phase 1b Study Evaluating R289 in Patients with Lower-Risk MDS at the 67th ASH Annual Meeting and ExpositionPR Newswire
Incyte’s First-in-Class mutCALR-Targeted Monoclonal Antibody, INCA033989, Granted Breakthrough Therapy Designation by U.S. FDABusiness Wire
Incyte Announces New Positive Data for INCA033989, its First-In-Class mutCALR-Targeted Monoclonal Antibody, in Patients with Myelofibrosis Presented at ASH 2025Business Wire
Pilot union strike notice: Air Transat will have to implement gradual and orderly shutdown planCanada Newswire
Nayax Considering an Offering of Notes and Warrants in IsraelGlobeNewswire
Yescarta® Delivers Consistent Safety, Efficacy, and Quality of Life Benefits Across Broad Range of Relapsed/Refractory Large B-cell Lymphoma Patients in New Analysis at ASH 2025Business Wire
Genmab Presents Pivotal Phase 3 Data from EPCORE® FL-1 Trial Demonstrating Clinical Benefit of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide (R²) in Patients with Relapsed or Refractory Follicular LymphomaBusiness Wire
Prime Medicine Announces The New England Journal of Medicine Publication of PM359 Clinical Data for the Treatment of Chronic Granulomatous DiseaseGlobeNewswire
ALX Oncology Announces Positive Results from Ongoing Investigator-Sponsored Phase 2 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with Indolent B-cell Non-Hodgkin Lymphoma, at ASH Annual MeetingGlobeNewswire
Genmab Presents Pivotal Phase 3 Data from EPCORE® FL-1 Trial Demonstrating Clinical Benefit of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide (R2) in Patients with Relapsed or Refractory Follicular LymphomaGlobeNewswire
Molecular Partners Presents Updated Data from Ongoing Phase 1/2a Trial of MP0533 in AML at ASH Annual MeetingGlobeNewswire
CARsgen's CAR-T Product Zevor-Cel Included in China's Commercial Health Insurance Innovative Drug CataloguePR Newswire
All Approved Indications of Five Akeso's Innovative Drugs Included in China's Latest NRDL: Featuring Two First-in-Class Bispecifics with New First-Line Indications and Three Newly Negotiated DrugsPR Newswire
Zai Lab Announces Updates to China’s National Reimbursement Drug ListBusiness Wire
Innovent Announces Inclusion of Seven Innovative Drugs including TYVYT New Indication and SYCUME in China's National Reimbursement Drug ListPR Newswire
University of Wisconsin Wins Abbott and Big Ten's 'We Give Blood' Competition as Campaign Donations Surge 319%, Helping Save Nearly 250,000 LivesPR Newswire
RNS announcements are delayed by up to an hour.
...